Telemedicine in Obesity

Telemedicine has reshaped obesity care access with rapid post-pandemic expansion. The session covers direct-to-consumer GLP-1 telehealth platforms (Ro, Hims, Sequence/Weight Watchers), post-2025 FDA compounding action and the regulatory landscape, outcomes comparison telehealth vs in-person obesity care, equity in telehealth access, hybrid care models, and the regulatory landscape considerations. Discussion addresses safety in DTC GLP-1 including missing pregnancy and eating-disorder screening, the role of integrated multidisciplinary care vs DTC, the cost-comparison telehealth vs traditional care, the international landscape, and emerging digital therapeutics integrated with pharmacotherapy.